The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | How can durvalumab be used in NSCLC?
Sanjay Popat, BSc MBBS FRCP PhD, from the Royal Marsden Hospital, London, UK, discusses highlights from the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The PACIFIC study (NCT02125461) was a large, randomised Phase III trial investigating the use of durvalumab in non-small cell lung cancer patients who had completed concomitant chemo-radiotherapy. This trial had a combined endpoint of progression free and overall survival, with durvalumab being significantly superior to placebo. Durvalumab could be considered as consolidation therapy for patients completing thoracic chemoradiotherapy.
